Viral Safety Approaches For Advanced Therapy Medicinal Products
Source: Parenteral Drug Association (PDA)
By Thomas R. Kreil, Ph.D., Shire

The availability of plasma-derived medicinal products— one of the earliest achievements of medical biotechnology—has enabled great progress in the treatment of specialized conditions such as hemophilia and immune deficiencies. Yet early on, the biologic materials used to develop these products were also found to be vulnerable to infectious disease agents. Today, manufacturers safeguard these products during the development process through a set of measures commonly referred to as the “Safety Tripod.”
VIEW THE ARTICLE!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Pharmaceutical Online? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
Parenteral Drug Association (PDA)
This website uses cookies to ensure you get the best experience on our website. Learn more